This is seen in the high frequency of TpC* mutations in potential “driver” mutations, including missense TpC* mutations in well-known genes such as KMTD2 and ATM shared across all tumours of a patient (Additional file 6: Table S2). The gene discussed is ATM; the disease is neoplasm.